Although our study is limited by its relatively small sample size, measurements of FGF23 at only one-time point, and the lack of vitamin D measurements, and DEXA scan, it provides the first evaluation of its potential role in cardiovascular and kidney disease in non-diabetic HIV-positive participants with clinically normal kidney function at baseline compared and with longitudinal follow-up for 3 years. This evidence concerns the gene FGF23 and kidney disorder.